palladone Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Palladone, and when can generic versions of Palladone launch?
Palladone is a drug marketed by Purdue Pharma Lp and is included in one NDA.
The generic ingredient in PALLADONE is hydromorphone hydrochloride. There are fourteen drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the hydromorphone hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Palladone
A generic version of palladone was approved as hydromorphone hydrochloride by HIKMA on July 29th, 1998.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for palladone?
- What are the global sales for palladone?
- What is Average Wholesale Price for palladone?
Summary for palladone
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 24 |
| Clinical Trials: | 1 |
| Patent Applications: | 5,827 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for palladone |
| DailyMed Link: | palladone at DailyMed |
Recent Clinical Trials for palladone
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of Miami | Phase 2 |
US Patents and Regulatory Information for palladone
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Purdue Pharma Lp | PALLADONE | hydromorphone hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 021044-001 | Sep 24, 2004 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Purdue Pharma Lp | PALLADONE | hydromorphone hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 021044-004 | Sep 24, 2004 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Purdue Pharma Lp | PALLADONE | hydromorphone hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 021044-002 | Sep 24, 2004 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Purdue Pharma Lp | PALLADONE | hydromorphone hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 021044-003 | Sep 24, 2004 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for palladone
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Purdue Pharma Lp | PALLADONE | hydromorphone hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 021044-002 | Sep 24, 2004 | ⤷ Sign Up | ⤷ Sign Up |
| Purdue Pharma Lp | PALLADONE | hydromorphone hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 021044-004 | Sep 24, 2004 | ⤷ Sign Up | ⤷ Sign Up |
| Purdue Pharma Lp | PALLADONE | hydromorphone hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 021044-003 | Sep 24, 2004 | ⤷ Sign Up | ⤷ Sign Up |
| Purdue Pharma Lp | PALLADONE | hydromorphone hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 021044-003 | Sep 24, 2004 | ⤷ Sign Up | ⤷ Sign Up |
| Purdue Pharma Lp | PALLADONE | hydromorphone hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 021044-001 | Sep 24, 2004 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for palladone
See the table below for patents covering palladone around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Egypt | 20600 | Sustained release compositions and a method of preparing pharmaceutical compositions | ⤷ Sign Up |
| Hungary | T77626 | ⤷ Sign Up | |
| Germany | 699436 | ⤷ Sign Up | |
| Israel | 110014 | Solid controlled-release oral dosage forms of opioid analgesics | ⤷ Sign Up |
| Hungary | 9402007 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
